Vestcor Inc raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 185,188 shares of the company’s stock after buying an additional 4,490 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of Vestcor Inc’s holdings, making the stock its 10th largest holding. Vestcor Inc’s holdings in Johnson & Johnson were worth $38,325,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the stock. Peachtree Investment Partners LLC boosted its stake in shares of Johnson & Johnson by 22.9% during the 4th quarter. Peachtree Investment Partners LLC now owns 9,156 shares of the company’s stock worth $1,895,000 after acquiring an additional 1,705 shares in the last quarter. MCF Advisors LLC boosted its stake in shares of Johnson & Johnson by 21.1% during the 4th quarter. MCF Advisors LLC now owns 18,969 shares of the company’s stock worth $3,926,000 after acquiring an additional 3,309 shares in the last quarter. First Command Advisory Services Inc. boosted its stake in shares of Johnson & Johnson by 8.2% during the 4th quarter. First Command Advisory Services Inc. now owns 14,419 shares of the company’s stock worth $2,984,000 after acquiring an additional 1,091 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its stake in shares of Johnson & Johnson by 10.0% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 452,586 shares of the company’s stock worth $93,663,000 after acquiring an additional 41,073 shares in the last quarter. Finally, Patron Partners LLC boosted its stake in shares of Johnson & Johnson by 1.7% during the 4th quarter. Patron Partners LLC now owns 10,359 shares of the company’s stock worth $2,144,000 after acquiring an additional 178 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.
Key Johnson & Johnson News
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Jim Cramer highlighted Johnson & Johnson’s lack of major patent expirations and pointed to its billion-dollar drugs and growing businesses as reasons to own the stock. Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
- Positive Sentiment: ASCO 2026 updates underscored Johnson & Johnson’s expanding specialty-drug pipeline, with encouraging data in autoimmunity, oncology, and myeloma that could support longer-term revenue growth. ASCO 2026 Data Underscore Johnson & Johnson’s Expanding Specialty Drug Story
- Positive Sentiment: Separate market coverage noted Johnson & Johnson has been outperforming the broader market recently, reinforcing investor confidence in the defensive healthcare name. Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
- Neutral Sentiment: Newsweek named Johnson & Johnson among the world’s greenest companies for 2026, which is supportive for ESG-focused investors but unlikely to move the stock on its own. Goldman Sachs, Johnson & Johnson, MetLife Named Among Newsweek’s World’s Greenest Companies 2026
- Neutral Sentiment: Analysts highlighted ongoing headwinds, including Stelara erosion, China MedTech pressure, and talc litigation, though J&J is still targeting $100 billion in revenue and faster growth in 2026. Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter last year, the company earned $2.77 EPS. The company’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.34 dividend. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is 61.97%.
Analysts Set New Price Targets
Several analysts have recently issued reports on the company. Rothschild & Co Redburn upped their price target on Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research note on Thursday, February 19th. Daiwa Securities Group upped their price target on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Weiss Ratings downgraded Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, April 24th. TD Cowen started coverage on Johnson & Johnson in a research note on Wednesday, April 8th. They set a “buy” rating and a $250.00 price target for the company. Finally, Stifel Nicolaus increased their target price on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.04.
Read Our Latest Stock Analysis on JNJ
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- MarketBeat Week in Review – 06/01 – 06/05
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
